In addition, several emerging GLP-1 medicines simultaneously target receptors for hormones such as GIP, glucagon, and amylin and are currently being evaluated for the treatment of obesity and related metabolic conditions (2–4). Here, GCG is linked to obesity due to melanocortin 4 receptor deficiency.